Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Advances in hepatitis C treatment. Why aren’t they being used?

Nezam H. Afdhal, MD
Conditions
February 7, 2015
Share
Tweet
Share

The really incredible advances in the treatment of hepatitis C bring to life several relevant questions as we move forward into 2015. First, who should be treating hepatitis C patients (primary care providers, gastroenterologists, infectious disease specialists)? Second, can we really afford to use these new treatments? I recently discussed this topic with my GI and hepatology colleagues in AGA Perspectives, the bi-monthly opinion magazine of the American Gastroenterological Association, but it’s time we extend this conversation outside of our community.

First, let’s consider sofosbuvir and ledipasvir, a single fixed-dose combination pill with over a 95 percent cure rate that was approved by the FDA for genotype 1 HCV in October 2014. Like other all-oral direct-acting antivirals, the simplicity, safety and effectiveness of this treatment should enable almost any physician with an interest in HCV to treat a patient. The pretreatment workup consists of simple blood tests, genotyping and determination of viral load and staging of disease with non-invasive serum tests such as FibroTest or a FibroScan to determine the presence of advanced fibrosis or cirrhosis. Patients at risk of advanced liver disease should undergo specialty evaluation by either a specialist infection disease (ID) physician or gastroenterologist, while patients who pass these tests can likely be treated in a primary care setting.

Unfortunately, although I truly believe that hepatitis C can be easily treated within the community including by internists and family physicians, the reality is that issues associated with both the cost of treatment and access to therapy have made this extremely difficult. Hepatitis C medications cost almost $100,000 or more for a full course of treatment and thus represent a significant burden on the health care system. If, over the course of the next 10 years, we treat 1 million patients — which is necessary if we are to impact the natural history of disease — then the cost to the health care system would be almost $100 billion.

This high cost of therapy has resulted in prioritization of care with restricted access for some patients. Currently, the majority of third-party payers and state Medicaid have limited access to those patients with advanced fibrosis or cirrhosis. And recently, the news has been about exclusivity deals between pharmacies and health plans and the makers of hepatitis C treatments.

In our practice, we have found that the current restrictions require almost one or two full-time personnel to devote continuous effort to help patients obtain treatment. In smaller GI or ID practices, this would create both unnecessary expense and significant effort. It is hard to imagine that an average internal medicine or family practice would have the resources to devote the time and personnel needed to obtain prior approval and authorization for treatment of any significant number of hepatitis C patients. In addition, certain state Medicaid plans — such as New York — have suggested that treatment only be provided by physicians with documented and proven experience in managing HCV patients.

In my experience, this potential rationing of health care to only those with advanced disease makes little clinical or pharmacoeconomic sense. Treatment duration can be shortened in patients that do not have cirrhosis resulting in a lower cost per sustained virologic response. In addition, these patients have reported equal improvements in a variety of physical, emotional and health-related outcomes as is reported for patients with more advanced disease.

Finally, it is ironic that here we are with the ability to essentially eradicate hepatitis C from the U.S. population within the next decade using simple, safe and highly effective therapies, and yet we appear to lack both the economic, societal and political wherewithal to make this a reality. The conversations must continue: How can we make this incredible opportunity a reality for our patients?

Nezam H. Afdhal is director of hepatology, Beth Israel Deaconess Medical Center, Boston, MA.

Prev

Touching a life on the other side of the world

February 6, 2015 Kevin 0
…
Next

You may not want this vaccine. But after watching this, you may want to think again.

February 7, 2015 Kevin 0
…

Tagged as: Gastroenterology, Medications

Post navigation

< Previous Post
Touching a life on the other side of the world
Next Post >
You may not want this vaccine. But after watching this, you may want to think again.

ADVERTISEMENT

More in Conditions

  • Why psychotherapy works and why psychotherapy fails

    Peggy A. Rothbaum, PhD
  • How oral health silently affects your heart, brain, and body

    Charles Reinertsen, DMD
  • How President Biden’s cognitive health shapes political and legal trust

    Muhamad Aly Rifai, MD
  • The emotional first responders of aesthetic medicine

    Sarah White, APRN
  • Why testosterone matters more than you think in women’s health

    Andrea Caamano, MD
  • How veteran health care is being transformed by tech and teamwork

    Deborah Lafer Scher
  • Most Popular

  • Past Week

    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • How regulatory overreach is destroying innovation in U.S. health care

      Kayvan Haddadan, MD | Physician
    • Why the U.S. mental health care system is failing and how to fix it [PODCAST]

      The Podcast by KevinMD | Podcast
    • The unseen cost of detachment in radiology

      Dr. Yesu Raju | Physician
    • I thought success was a destination. Then I became a doctor.

      Ryan Nadelson, MD | Physician
    • Why psychotherapy works and why psychotherapy fails

      Peggy A. Rothbaum, PhD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • How regulatory overreach is destroying innovation in U.S. health care

      Kayvan Haddadan, MD | Physician
    • Why the U.S. mental health care system is failing and how to fix it [PODCAST]

      The Podcast by KevinMD | Podcast
    • The unseen cost of detachment in radiology

      Dr. Yesu Raju | Physician
    • I thought success was a destination. Then I became a doctor.

      Ryan Nadelson, MD | Physician
    • Why psychotherapy works and why psychotherapy fails

      Peggy A. Rothbaum, PhD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...